Success Stories: EB-1A Approved for Assistant Staff Scientist in Oklahoma in the Field of Pharmacology
Client’s Testimonial:
Awesome! Many thanks for your help. I will surely share my great experience with you on MitBBS, and recommend you to my friends!
Position at the Time of Case Filing: Assistant Staff Scientist
Country of Origin: China
Service Center: Texas Service Center (TSC)
State of Residence at the Time of Filing: Oklahoma
Approval Notice Date: September 22th, 2014
Processing Time: 1 Month, 10 Days (10 Days after Premium Processing Requested)
In this case, the client that we had the opportunity to work with was an Assistant Staff Scientist from China in the field of Pharmacology. His specialized research had focused on diabetes and its complications, including diabetic nephrophathy, diabetic cardiomyopathy, and atherosclerosis. His work had resulted in 11 peer-reviewed scientific articles and 5 presentations at national and international conferences; at the time that his case was filed, his publications had been cited at least 264 times by independent and leading researchers from prestigious institutions and organizations around the world, indicating the major significance of his work. He had also reviewed 18 manuscripts for distinctive, internationally-circulated journals. His superior level of expertise was confirmed in the following quote from an independent recommender, “[…][Client] has developed a new genetic method to activate the smooth muscle cells in mice and produce more human-like atherosclerosis over the last three years. [Client] found that activated smooth muscle cells intensely increase the initiation of atherosclerosis and support the development of advanced plaques with vulnerable features. The vulnerable features found on the advanced plaques strongly resemble, in many respects, the pathology seen in human patients.” It was our goal to prove that our client qualified for classification as an Alien of Extraordinary Ability given that he sought to remain in the United States to continue work in the area of Pharmacology, and that his continued research would substantially and prospectively benefit the United States. With the proof and documentation that we provided, his case was approved in 1 month and 10 days.